Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert S Coffin

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Current Opinion in Virology|June 30, 2015
From virotherapy to oncolytic immunotherapy: where are we now?Robert S Coffin
Expert Opinion on Biological Therapy|April 28, 2010
Delivery of RNA interference triggers to sensory neurons in vivo using herpes simplex virusAnna-Maria Anesti, Robert S Coffin
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor controlGuy R Simpson, Robert S Coffin
Nucleic Acids Research|June 28, 2008
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virusAnna-Maria Anesti, Pieter J Peeters, Ines Royaux, et al.
Biotechnology Progress|February 8, 2003
Impact of process conditions on the centrifugal recovery of a disabled herpes simplex virusPantea Lotfian, M Susana Levy, Robert S Coffin, et al.
Oncolytic Virotherapy|August 12, 2016
Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanomaTasha Hughes, Robert S Coffin, Caroline E Lilley, et al.
BMC Cancer|September 15, 2010
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivoAnna-Maria Anesti, Guy R Simpson, Toby Price, et al.
Neurosurgery|September 21, 2007
Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemiaYoshihito Miki, Naosuke Nonoguchi, Naokado Ikeda, et al.
Cancer Research|May 3, 2006
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor controlGuy R Simpson, Ziqun Han, Binlei Liu, et al.
Brain Research. Molecular Brain Research|March 26, 2003
Heat shock protein 27 delivered via a herpes simplex virus vector can protect neurons of the hippocampus against kainic-acid-induced cell lossStephan A Kalwy, Mohammed T Akbar, Robert S Coffin, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Current Opinion in Virology|June 30, 2015
From virotherapy to oncolytic immunotherapy: where are we now?Robert S Coffin
Expert Opinion on Biological Therapy|April 28, 2010
Delivery of RNA interference triggers to sensory neurons in vivo using herpes simplex virusAnna-Maria Anesti, Robert S Coffin
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor controlGuy R Simpson, Robert S Coffin
Nucleic Acids Research|June 28, 2008
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virusAnna-Maria Anesti, Pieter J Peeters, Ines Royaux, et al.
Biotechnology Progress|February 8, 2003
Impact of process conditions on the centrifugal recovery of a disabled herpes simplex virusPantea Lotfian, M Susana Levy, Robert S Coffin, et al.
Oncolytic Virotherapy|August 12, 2016
Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanomaTasha Hughes, Robert S Coffin, Caroline E Lilley, et al.
BMC Cancer|September 15, 2010
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivoAnna-Maria Anesti, Guy R Simpson, Toby Price, et al.
Neurosurgery|September 21, 2007
Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemiaYoshihito Miki, Naosuke Nonoguchi, Naokado Ikeda, et al.
Cancer Research|May 3, 2006
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor controlGuy R Simpson, Ziqun Han, Binlei Liu, et al.
Brain Research. Molecular Brain Research|March 26, 2003
Heat shock protein 27 delivered via a herpes simplex virus vector can protect neurons of the hippocampus against kainic-acid-induced cell lossStephan A Kalwy, Mohammed T Akbar, Robert S Coffin, et al.
Pageof 3